Site name unknown Seattle 98195

Phase [desc]	Trial	Trial Status	Site Status	Drug	NCT#
1	A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors	Ongoing, but not recruiting	Closed	Cobimetinib + MPDL3280A	NCT01988896